Respiratory

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.

Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.

Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.

ARS will compete directly with EpiPen and other injectable products with inhaled neffy as the first needle-free epinephrine therapy for severe allergy attacks. EU approval is thought imminent.

Second quarter revenues are up but RSV jab woes drag on the company’s stock.    

The deal includes up to 10 medicines, with an initial focus on immunology and respiratory diseases, and is similar to one the VC firm made with Pfizer last year.

With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.    

The French drugmaker can now boast seven approvals for its huge-earning IL-4/IL-13 inhibitor.

The respiratory specialist is set to hit the ground running with Ohtuvayre, the first COPD inhaled product with a novel mechanism of action to be approved in over two decades.

Five years after a Phase III failure, Savara reports pivotal data supporting approval of molgramostim as the first drug for autoimmune pulmonary alveolar proteinosis.

Sanofi and Regeneron could have the first biologic on the market for COPD – and a potentially better one is in the works.    

The drug maker anticipates a smooth regulatory path and has already begun to rapidly expand its sales force across most of the US.

The company is adopting a two-pronged strategy to capitalize on its presence in the country to expand the market for its inhaled therapies and biologics for asthma and COPD.

In this week's podcast edition of Five Must-Know Things: Biogen’s immunology acquisition; AstraZeneca looks to cement respiratory lead; why US FTC is tough on pharma; the US election’s impact on pharma; and how new AI tools are impacting medical affairs. 

The twice-yearly depemokimab will soon head to the regulators, but it will need to succeed repeatedly if it is to make the £3bn peak sales GSK is hoping for.    

Anti-TSLP antibody Tezspire (tezepelumab) showed efficacy in a Phase IIa study versus placebo in COPD patients with lower eosinophil levels than those tested in Dupixent’s pivotal studies.

The biotech plans to run a Phase II study of ENV-101 in IPF and PPF, followed by a Phase III study that would start in 2026.